Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Muscular Dystrophy Association (MDA) has awarded $120,000 to US-based Catabasis Pharmaceuticals, to evaluate two compounds called CAT-1004 and CAT-1040 in the mdx research mouse model of Duchenne muscular dystrophy (DMD).
Subscribe to our email newsletter
MDA translational research director Jane Larkindale said the grant will help to support further testing of CAT-1004 to assess the compound’s ability to counter muscle-damaging inflammation and support muscle regeneration.
The company plans to determine in the new four-month study whether either or both CAT-1004 and CAT-1040 reduce inflammation in muscle tissue and improve muscle function.
Catabasis co-founder and chief scientific officer Michael Jirousek said the short-term preclinical findings in DMD models are encouraging, and they look forward to conducting the longer-term study with both CAT-1004 and CAT-1040.
In a previous MDA-supported mouse study, CAT-1004 as well as prednisolone reduced muscle inflammation without the prednisolone side effect of reduced muscle weight.
The completed phase 1 safety, tolerability and pharmacokinetics study of CAT-1004 in healthy human volunteers demonstrated that the drug was safe and well-tolerated.